A Look At Revvity (RVTY) Valuation As Mixed Recent Returns Contrast With Undervaluation Narrative

Clinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease Risk

Endpoints NewsEli Lilly's claims data deadline may kick off new 340B fight

Clinical OMICsFirst Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results

AgilentAgilent Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026 - the-scientist.com

Endpoints NewsGrace Science says FDA bottleneck jeopardizes rare disease therapy

Clinical OMICsDigital Pathology and the NHS: Overcoming Barriers to a More Connected Future

FierceBiotechFueled by M&A and partnerships, biotech is poised for continued growth: EY

FierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market

BioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studies

Endpoints NewsA different approach to lowering healthcare costs

CellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity

Clinical OMICsDiabetes Drug Linked to Reduced Heart Failure in High-Risk Gene Carriers